Review on clinical application of Saxagliptin and Metformin Extended-Release (XR)fix-dose combination tablet in type 2 diabetes / 中国糖尿病杂志
Chinese Journal of Diabetes
; (12): 91-94, 2017.
Article
em Zh
| WPRIM
| ID: wpr-508336
Biblioteca responsável:
WPRO
ABSTRACT
[Summary] There is a complementary or synergistic action of saxagliptin and metformin when used in combination. Combination therapy with saxagliptin and metformin can effectively reduce blood glucose and body weight with a low risk of hypoglycemia in patients with diabetes. Additionally,the cardiovascular safety of saxagliptin has been confirmed by the SAVOR study,whereas a cardiovascular protective effect of metformin has been demonstrated by the UKPDS study. As being taken orally once daily,saxagliptin and metformin extended-release fix-dose combination tablet can further improve patients′compliance and adherence. According to the guidelines,this tablet could be recommended as the initial treatment for newlydiagnosed type 2 diabetes with HbA1 c higher than 7. 5%,or in those with inadequately glycemic control under metformin monotherapy.
Texto completo:
1
Índice:
WPRIM
Tipo de estudo:
Guideline
Idioma:
Zh
Revista:
Chinese Journal of Diabetes
Ano de publicação:
2017
Tipo de documento:
Article